Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kristin A. Plichta, Stephen A. Graves, John M. Buatti
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	theranostics PSMA oligometastatic prostate cancer Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/e9d9fc024dc8467ab1dd9078ae9a8eb3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9d9fc024dc8467ab1dd9078ae9a8eb3
record_format	dspace
spelling	oai:doaj.org-article:e9d9fc024dc8467ab1dd9078ae9a8eb32021-11-25T17:53:23ZProstate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer10.3390/ijms2222120951422-00671661-6596https://doaj.org/article/e9d9fc024dc8467ab1dd9078ae9a8eb32021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12095https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers. Diagnostic PSMA radiopharmaceuticals are currently used for staging and diagnosis of prostate cancers, and imaging can predict response to therapeutic PSMA radiopharmaceuticals. While mainly used in the setting of metastatic, castrate-resistant disease, clinical trials are investigating the use of PSMA-based therapy at earlier stages, including in hormone-sensitive or hormone-naïve prostate cancers, and in oligometastatic prostate cancers. This review explores the use of PSMA as a theranostic target and investigates the potential use of PSMA in earlier stage disease, including hormone-sensitive metastatic prostate cancer, and oligometastatic prostate cancer.Kristin A. PlichtaStephen A. GravesJohn M. BuattiMDPI AGarticletheranosticsPSMAoligometastatic prostate cancerBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12095, p 12095 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	theranostics PSMA oligometastatic prostate cancer Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	theranostics PSMA oligometastatic prostate cancer Biology (General) QH301-705.5 Chemistry QD1-999 Kristin A. Plichta Stephen A. Graves John M. Buatti Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
description	Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment of prostate cancers. Diagnostic PSMA radiopharmaceuticals are currently used for staging and diagnosis of prostate cancers, and imaging can predict response to therapeutic PSMA radiopharmaceuticals. While mainly used in the setting of metastatic, castrate-resistant disease, clinical trials are investigating the use of PSMA-based therapy at earlier stages, including in hormone-sensitive or hormone-naïve prostate cancers, and in oligometastatic prostate cancers. This review explores the use of PSMA as a theranostic target and investigates the potential use of PSMA in earlier stage disease, including hormone-sensitive metastatic prostate cancer, and oligometastatic prostate cancer.
format	article
author	Kristin A. Plichta Stephen A. Graves John M. Buatti
author_facet	Kristin A. Plichta Stephen A. Graves John M. Buatti
author_sort	Kristin A. Plichta
title	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
title_short	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
title_full	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
title_fullStr	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
title_full_unstemmed	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
title_sort	prostate-specific membrane antigen (psma) theranostics for treatment of oligometastatic prostate cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e9d9fc024dc8467ab1dd9078ae9a8eb3
work_keys_str_mv	AT kristinaplichta prostatespecificmembraneantigenpsmatheranosticsfortreatmentofoligometastaticprostatecancer AT stephenagraves prostatespecificmembraneantigenpsmatheranosticsfortreatmentofoligometastaticprostatecancer AT johnmbuatti prostatespecificmembraneantigenpsmatheranosticsfortreatmentofoligometastaticprostatecancer
_version_	1718411896395137024

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

Ejemplares similares